Study finds patients with complex fibroadenomas can avoid surgery

Feb 11, 2008

Complex fibroadenomas have a low incidence of malignancy, so women with this condition can be more conservatively treated and avoid surgical biopsy, according to a new study by a team of researchers from the Hadassah-Hebrew University Medical Center in Jerusalem.

A fibroadenoma is a benign growth of the breast that is common in young women. They are not usually associated with breast cancer, and are often diagnosed with simple ultrasound-guided, non-surgical biopsy. Complex fibroadenomas are a subtype of fibroadenomas. They are also benign, but they have calcifications and small cysts that make their pathology more complex than simple fibroadenomas, prompting many doctors to recommend surgical removal to ensure that the fibroadenoma is not malignant.

“There is a lack of information or guidelines in the medical literature about the management of complex fibroadenomas, causing a dilemma for doctors with patients who have these lesions. Because the management of these patients is not clear, there is a tendency to excise them on surgery following a needle biopsy,” said Miri Sklair-Levy, MD, lead author of the study.

For the study, the researchers evaluated the clinical and imaging presentations of biopsy-proven complex fibroadenomas in 63 patients, compared pathologies and sizes of the lesions, and then followed up after two years. They found that only one out of the 63 patients with complex fibroadenomas had a malignancy, and that the patient with a malignancy had already shown previously.

“The findings from our study showed that complex fibroadenomas can be treated similar to simple fibroadenomas, meaning follow-up without the need to excise the lesions surgically. The exception to this practice would be if some atypical high-risk lesions are found, as in the case with the one patient in our study. In those situations, the complex fibroadenomas should be surgically excised to rule out malignancy,” said Dr. Sklair-Levy.

Source: American Roentgen Ray Society

Explore further: Amgen misses 1Q views as higher costs cut profit

add to favorites email to friend print save as pdf

Related Stories

First-of-its-kind NASA space-weather project

6 hours ago

A NASA scientist is launching a one-to-two-year pilot project this summer that takes advantage of U.S. high-voltage power transmission lines to measure a phenomenon that has caused widespread power outages ...

US urged to drop India WTO case on solar

6 hours ago

Environmentalists Wednesday urged the United States to drop plans to haul India to the WTO to open its solar market, saying the action would hurt the fight against climate change.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Man among first in US to get 'bionic eye' (Update)

A degenerative eye disease slowly robbed Roger Pontz of his vision. Diagnosed with retinitis pigmentosa as a teenager, Pontz has been almost completely blind for years. Now, thanks to a high-tech procedure ...